Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

A Pilot Study of Liposomal Doxorubicin Combined with Bevacizumab followed by Bevacizumab Monotherapy in Patients with Advanced Kaposi Sarcoma.

Ramaswami R, Uldrick TS, Polizzotto MN, Wyvill KM, Goncalves P, Widell A, Lurain K, Steinberg SM, Figg WD, Tosato G, Whitby D, Yarchoan R.

Clin Cancer Res. 2019 Jul 15;25(14):4238-4247. doi: 10.1158/1078-0432.CCR-18-3528. Epub 2019 Apr 12.

PMID:
30979736
2.

Viral, immunologic, and clinical features of primary effusion lymphoma.

Lurain K, Polizzotto MN, Aleman K, Bhutani M, Wyvill KM, Gonçalves PH, Ramaswami R, Marshall VA, Miley W, Steinberg SM, Little RF, Wilson W, Filie AC, Pittaluga S, Jaffe ES, Whitby D, Yarchoan R, Uldrick TS.

Blood. 2019 Apr 18;133(16):1753-1761. doi: 10.1182/blood-2019-01-893339. Epub 2019 Feb 19.

3.

Metagenomic Discovery of 83 New Human Papillomavirus Types in Patients with Immunodeficiency.

Pastrana DV, Peretti A, Welch NL, Borgogna C, Olivero C, Badolato R, Notarangelo LD, Gariglio M, FitzGerald PC, McIntosh CE, Reeves J, Starrett GJ, Bliskovsky V, Velez D, Brownell I, Yarchoan R, Wyvill KM, Uldrick TS, Maldarelli F, Lisco A, Sereti I, Gonzalez CM, Androphy EJ, McBride AA, Van Doorslaer K, Garcia F, Dvoretzky I, Liu JS, Han J, Murphy PM, McDermott DH, Buck CB.

mSphere. 2018 Dec 12;3(6). pii: e00645-18. doi: 10.1128/mSphereDirect.00645-18.

4.

Polymorphisms in KSHV-encoded microRNA sequences affect levels of mature viral microRNA in Kaposi Sarcoma lesions.

Marshall VA, Labo N, Sztuba-Solinska J, Cornejo Castro EM, Aleman K, Wyvill KM, McNamara L, Le Grice SFJ, Yarchoan R, Uldrick TS, MacPhail P, Polizzotto MN, Whitby D.

Oncotarget. 2018 Nov 9;9(88):35856-35869. doi: 10.18632/oncotarget.26321. eCollection 2018 Nov 9.

5.

T-cell responses to KSHV infection: a systematic approach.

Roshan R, Labo N, Trivett M, Miley W, Marshall V, Coren L, Cornejo Castro EM, Perez H, Holdridge B, Davis E, Matus-Nicodemos R, Ayala VI, Sowder R 2nd, Wyvill KM, Aleman K, Fennessey C, Lifson J, Polizzotto MN, Douek D, Keele B, Uldrick TS, Yarchoan R, Ohlen C, Ott D, Whitby D.

Oncotarget. 2017 Nov 25;8(65):109402-109416. doi: 10.18632/oncotarget.22683. eCollection 2017 Dec 12.

6.

Evidence for a Mesothelial Origin of Body Cavity Effusion Lymphomas.

Sanchez-Martin D, Uldrick TS, Kwak H, Ohnuki H, Polizzotto MN, Annunziata CM, Raffeld M, Wyvill KM, Aleman K, Wang V, Marshall VA, Whitby D, Yarchoan R, Tosato G.

J Natl Cancer Inst. 2017 Sep 1;109(9). doi: 10.1093/jnci/djx016.

7.

A Phase Ib Study of Sorafenib (BAY 43-9006) in Patients with Kaposi Sarcoma.

Uldrick TS, Gonçalves PH, Wyvill KM, Peer CJ, Bernstein W, Aleman K, Polizzotto MN, Venzon D, Steinberg SM, Marshall V, Whitby D, Little RF, Wright JJ, Rudek MA, Figg WD, Yarchoan R.

Oncologist. 2017 May;22(5):505-e49. doi: 10.1634/theoncologist.2016-0486. Epub 2017 Mar 24.

8.

Pomalidomide for Symptomatic Kaposi's Sarcoma in People With and Without HIV Infection: A Phase I/II Study.

Polizzotto MN, Uldrick TS, Wyvill KM, Aleman K, Peer CJ, Bevans M, Sereti I, Maldarelli F, Whitby D, Marshall V, Goncalves PH, Khetani V, Figg WD, Steinberg SM, Zeldis JB, Yarchoan R.

J Clin Oncol. 2016 Dec;34(34):4125-4131. Epub 2016 Oct 31. Erratum in: J Clin Oncol. 2018 Jul 1;36(19):2008.

9.

Clinical Features and Outcomes of Patients With Symptomatic Kaposi Sarcoma Herpesvirus (KSHV)-associated Inflammation: Prospective Characterization of KSHV Inflammatory Cytokine Syndrome (KICS).

Polizzotto MN, Uldrick TS, Wyvill KM, Aleman K, Marshall V, Wang V, Whitby D, Pittaluga S, Jaffe ES, Millo C, Tosato G, Little RF, Steinberg SM, Sereti I, Yarchoan R.

Clin Infect Dis. 2016 Mar 15;62(6):730-738. doi: 10.1093/cid/civ996. Epub 2015 Dec 12. Erratum in: Clin Infect Dis. 2018 Mar 5;66(6):985.

10.

18F-fluorodeoxyglucose Positron Emission Tomography in Kaposi Sarcoma Herpesvirus-Associated Multicentric Castleman Disease: Correlation With Activity, Severity, Inflammatory and Virologic Parameters.

Polizzotto MN, Millo C, Uldrick TS, Aleman K, Whatley M, Wyvill KM, O'Mahony D, Marshall V, Whitby D, Maass-Moreno R, Steinberg SM, Little RF, Yarchoan R.

J Infect Dis. 2015 Oct 15;212(8):1250-60. doi: 10.1093/infdis/jiv204. Epub 2015 Mar 31.

11.

Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease.

Uldrick TS, Polizzotto MN, Aleman K, Wyvill KM, Marshall V, Whitby D, Wang V, Pittaluga S, O'Mahony D, Steinberg SM, Little RF, Yarchoan R.

Blood. 2014 Dec 4;124(24):3544-52. doi: 10.1182/blood-2014-07-586800. Epub 2014 Oct 20.

12.

Heterogeneity and breadth of host antibody response to KSHV infection demonstrated by systematic analysis of the KSHV proteome.

Labo N, Miley W, Marshall V, Gillette W, Esposito D, Bess M, Turano A, Uldrick T, Polizzotto MN, Wyvill KM, Bagni R, Yarchoan R, Whitby D.

PLoS Pathog. 2014 Mar 27;10(3):e1004046. doi: 10.1371/journal.ppat.1004046. eCollection 2014 Mar.

13.

A sensitive and robust HPLC assay with fluorescence detection for the quantification of pomalidomide in human plasma for pharmacokinetic analyses.

Shahbazi S, Peer CJ, Polizzotto MN, Uldrick TS, Roth J, Wyvill KM, Aleman K, Zeldis JB, Yarchoan R, Figg WD.

J Pharm Biomed Anal. 2014 Apr;92:63-8. doi: 10.1016/j.jpba.2014.01.001. Epub 2014 Jan 9.

14.

Evaluation of non-invasive multispectral imaging as a tool for measuring the effect of systemic therapy in Kaposi sarcoma.

Kainerstorfer JM, Polizzotto MN, Uldrick TS, Rahman R, Hassan M, Najafizadeh L, Ardeshirpour Y, Wyvill KM, Aleman K, Smith PD, Yarchoan R, Gandjbakhche AH.

PLoS One. 2013 Dec 27;8(12):e83887. doi: 10.1371/journal.pone.0083887. eCollection 2013.

15.

Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease.

Polizzotto MN, Uldrick TS, Wang V, Aleman K, Wyvill KM, Marshall V, Pittaluga S, O'Mahony D, Whitby D, Tosato G, Steinberg SM, Little RF, Yarchoan R.

Blood. 2013 Dec 19;122(26):4189-98. doi: 10.1182/blood-2013-08-519959. Epub 2013 Oct 30.

16.

Phase II study of bevacizumab in patients with HIV-associated Kaposi's sarcoma receiving antiretroviral therapy.

Uldrick TS, Wyvill KM, Kumar P, O'Mahony D, Bernstein W, Aleman K, Polizzotto MN, Steinberg SM, Pittaluga S, Marshall V, Whitby D, Little RF, Yarchoan R.

J Clin Oncol. 2012 May 1;30(13):1476-83. doi: 10.1200/JCO.2011.39.6853. Epub 2012 Mar 19.

17.

High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy.

Uldrick TS, Polizzotto MN, Aleman K, O'Mahony D, Wyvill KM, Wang V, Marshall V, Pittaluga S, Steinberg SM, Tosato G, Whitby D, Little RF, Yarchoan R.

Blood. 2011 Jun 30;117(26):6977-86. doi: 10.1182/blood-2010-11-317610. Epub 2011 Apr 12.

18.

An interleukin-6-related systemic inflammatory syndrome in patients co-infected with Kaposi sarcoma-associated herpesvirus and HIV but without Multicentric Castleman disease.

Uldrick TS, Wang V, O'Mahony D, Aleman K, Wyvill KM, Marshall V, Steinberg SM, Pittaluga S, Maric I, Whitby D, Tosato G, Little RF, Yarchoan R.

Clin Infect Dis. 2010 Aug 1;51(3):350-8. doi: 10.1086/654798.

19.

Distinct profiles of antibodies to Kaposi sarcoma-associated herpesvirus antigens in patients with Kaposi sarcoma, multicentric Castleman disease, and primary effusion lymphoma.

Burbelo PD, Issa AT, Ching KH, Wyvill KM, Little RF, Iadarola MJ, Kovacs JA, Yarchoan R.

J Infect Dis. 2010 Jun 15;201(12):1919-22. doi: 10.1086/652869.

20.

Treatment of AIDS-related Kaposi's sarcoma with interleukin-12: rationale and preliminary evidence of clinical activity.

Yarchoan R, Pluda JM, Wyvill KM, Aleman K, Rodriguez-Chavez IR, Tosato G, Catanzaro AT, Steinberg SM, Little RF.

Crit Rev Immunol. 2007;27(5):401-14. Review.

PMID:
18197804
21.

Phase 2 study of pegylated liposomal doxorubicin in combination with interleukin-12 for AIDS-related Kaposi sarcoma.

Little RF, Aleman K, Kumar P, Wyvill KM, Pluda JM, Read-Connole E, Wang V, Pittaluga S, Catanzaro AT, Steinberg SM, Yarchoan R.

Blood. 2007 Dec 15;110(13):4165-71. Epub 2007 Sep 10.

22.

Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma.

Little RF, Pluda JM, Wyvill KM, Rodriguez-Chavez IR, Tosato G, Catanzaro AT, Steinberg SM, Yarchoan R.

Blood. 2006 Jun 15;107(12):4650-7. Epub 2006 Feb 28.

23.

Persistent HIV-1 infection of natural killer cells in patients receiving highly active antiretroviral therapy.

Valentin A, Rosati M, Patenaude DJ, Hatzakis A, Kostrikis LG, Lazanas M, Wyvill KM, Yarchoan R, Pavlakis GN.

Proc Natl Acad Sci U S A. 2002 May 14;99(10):7015-20.

24.

Activity of thalidomide in AIDS-related Kaposi's sarcoma.

Little RF, Wyvill KM, Pluda JM, Welles L, Marshall V, Figg WD, Newcomb FM, Tosato G, Feigal E, Steinberg SM, Whitby D, Goedert JJ, Yarchoan R.

J Clin Oncol. 2000 Jul;18(13):2593-602.

PMID:
10893291
25.

A phase I trial of the pharmacokinetics, toxicity, and activity of KNI-272, an inhibitor of HIV-1 protease, in patients with AIDS or symptomatic HIV infection.

Humphrey RW, Wyvill KM, Nguyen BY, Shay LE, Kohler DR, Steinberg SM, Ueno T, Fukasawa T, Shintani M, Hayashi H, Mitsuya H, Yarchoan R.

Antiviral Res. 1999 Feb;41(1):21-33.

PMID:
10321576
26.

Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma.

Welles L, Saville MW, Lietzau J, Pluda JM, Wyvill KM, Feuerstein I, Figg WD, Lush R, Odom J, Wilson WH, Fajardo MT, Humphrey RW, Feigal E, Tuck D, Steinberg SM, Broder S, Yarchoan R.

J Clin Oncol. 1998 Mar;16(3):1112-21.

PMID:
9508198
27.

Kaposi's sarcoma (KS)-associated herpesvirus-like DNA sequences in peripheral blood mononuclear cells: association with KS and persistence in patients receiving anti-herpesvirus drugs.

Humphrey RW, O'Brien TR, Newcomb FM, Nishihara H, Wyvill KM, Ramos GA, Saville MW, Goedert JJ, Straus SE, Yarchoan R.

Blood. 1996 Jul 1;88(1):297-301.

PMID:
8704186
28.

Five-year follow-up of a phase I study of didanosine in patients with advanced human immunodeficiency virus infection.

Nguyen BY, Yarchoan R, Wyvill KM, Venzon DJ, Pluda JM, Mitsuya H, Broder S.

J Infect Dis. 1995 May;171(5):1180-9.

PMID:
7751692
29.

A randomized pilot study of alternating or simultaneous zidovudine and didanosine therapy in patients with symptomatic human immunodeficiency virus infection.

Yarchoan R, Lietzau JA, Nguyen BY, Brawley OW, Pluda JM, Saville MW, Wyvill KM, Steinberg SM, Agbaria R, Mitsuya H, et al.

J Infect Dis. 1994 Jan;169(1):9-17. Erratum in: J Infect Dis 1994 Jul;170(1):260.

PMID:
7903976
30.

A pilot study of sequential therapy with zidovudine plus acyclovir, dideoxyinosine, and dideoxycytidine in patients with severe human immunodeficiency virus infection.

Nguyen BY, Shay LE, Wyvill KM, Pluda JM, Brawley O, Cohen RB, Whitcup SM, Venzon DJ, Broder S, Yarchoan R.

J Infect Dis. 1993 Oct;168(4):810-7.

PMID:
8397267
31.

Didanosine use in the adult HIV patient.

Shay LE, Wyvill KM.

Nurse Pract. 1992 Dec;17(12):59-64. Review.

PMID:
1465232
32.

Plasma HIV-1 viremia in HIV-1 infected individuals assessed by polymerase chain reaction.

Aoki-Sei S, Yarchoan R, Kageyama S, Hoekzema DT, Pluda JM, Wyvill KM, Broder S, Mitsuya H.

AIDS Res Hum Retroviruses. 1992 Jul;8(7):1263-70.

PMID:
1520538
33.

Pharmacokinetics of 2',3'-dideoxyinosine in patients with severe human immunodeficiency infection. II. The effects of different oral formulations and the presence of other medications.

Hartman NR, Yarchoan R, Pluda JM, Thomas RV, Wyvill KM, Flora KP, Broder S, Johns DG.

Clin Pharmacol Ther. 1991 Sep;50(3):278-85.

PMID:
1914362
34.

CD4 count and the risk for death in patients infected with HIV receiving antiretroviral therapy.

Yarchoan R, Venzon DJ, Pluda JM, Lietzau J, Wyvill KM, Tsiatis AA, Steinberg SM, Broder S.

Ann Intern Med. 1991 Aug 1;115(3):184-9.

PMID:
1676252
35.

New drug therapy for patients with HIV. Nursing implications in the administration of 2',3'-dideoxyinosine (ddI).

Shay LE, Thomas RV, Wyvill KM, Adamo DO, Jenkins JF.

Cancer Nurs. 1990 Oct;13(5):269-77.

PMID:
2123127
36.

Long-term toxicity/activity profile of 2',3'-dideoxyinosine in AIDS or AIDS-related complex.

Yarchoan R, Pluda JM, Thomas RV, Mitsuya H, Brouwers P, Wyvill KM, Hartman N, Johns DG, Broder S.

Lancet. 1990 Sep 1;336(8714):526-9.

PMID:
1975038
37.

Development of non-Hodgkin lymphoma in a cohort of patients with severe human immunodeficiency virus (HIV) infection on long-term antiretroviral therapy.

Pluda JM, Yarchoan R, Jaffe ES, Feuerstein IM, Solomon D, Steinberg SM, Wyvill KM, Raubitschek A, Katz D, Broder S.

Ann Intern Med. 1990 Aug 15;113(4):276-82.

PMID:
1973886
38.

Initial clinical experience with dideoxynucleosides as single agents and in combination therapy.

Yarchoan R, Pluda JM, Perno CF, Mitsuya H, Thomas RV, Wyvill KM, Broder S.

Ann N Y Acad Sci. 1990;616:328-43. Review.

PMID:
2078027

Supplemental Content

Loading ...
Support Center